Holders — by stockHoldings — by fund
Opaleye Management Inc.
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001595855
$1.10B
disclosed book value
58
positions
17.7%
largest position share
Positions, as of 2026-06-30
top 58 of 58 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | LQDALIQUIDIA CORPORATION | 2.4M | $195.1M | 17.7% |
| 2 | ETONETON PHARMACEUTICALS INC | 2.9M | $103.5M | 9.4% |
| 3 | HROWHARROW INC | 2.4M | $101.9M | 9.2% |
| 4 | IRONDISC MEDICINE INC | 855,000 | $62.5M | 5.7% |
| 5 | UROGEN PHARMA LTD | 1.4M | $53.0M | 4.8% |
| 6 | APGEAPOGEE THERAPEUTICS INC | 390,000 | $51.8M | 4.7% |
| 7 | MEIRAGTX HLDGS PLC | 3.5M | $48.0M | 4.3% |
| 8 | SOL-GEL TECHNOLOGIES LTD | 500,000 | $37.1M | 3.4% |
| 9 | RZLTREZOLUTE INC | 6.3M | $32.8M | 3% |
| 10 | TGTXTG THERAPEUTICS INC | 535,000 | $29.4M | 2.7% |
| 11 | IMMXIMMIX BIOPHARMA INC | 2.3M | $24.2M | 2.2% |
| 12 | CRESCENT BIOPHARMA INC. | 1.3M | $23.7M | 2.2% |
| 13 | STOKSTOKE THERAPEUTICS INC | 700,000 | $22.9M | 2.1% |
| 14 | ACOGALPHA COGNITION INC | 2.9M | $20.9M | 1.9% |
| 15 | EWTXEDGEWISE THERAPEUTICS INC | 500,000 | $20.3M | 1.8% |
| 16 | RVMDREVOLUTION MEDICINES INC | 100,000 | $18.7M | 1.7% |
| 17 | GLUEMONTE ROSA THERAPEUTICS INC | 745,000 | $18.0M | 1.6% |
| 18 | ALMSALUMIS INC | 550,000 | $15.5M | 1.4% |
| 19 | CDXSCODEXIS INC | 6.8M | $15.3M | 1.4% |
| 20 | REPLREPLIMUNE GROUP INC | 1.4M | $15.3M | 1.4% |
| 21 | XOMA ROYALTY CORPORATION | 338,374 | $14.4M | 1.3% |
| 22 | MBXMBX BIOSCIENCES INC | 260,000 | $14.4M | 1.3% |
| 23 | RYTMRHYTHM PHARMACEUTICALS INC | 122,500 | $13.6M | 1.2% |
| 24 | EDITEDITAS MEDICINE INC | 3.9M | $12.5M | 1.1% |
| 25 | PTGXPROTAGONIST THERAPEUTICS INC | 100,000 | $12.3M | 1.1% |
| 26 | CABACABALETTA BIO INC | 3.9M | $12.0M | 1.1% |
| 27 | QTTBQ32 BIO INC | 931,000 | $11.9M | 1.1% |
| 28 | ANNXANNEXON INC | 1.7M | $9.8M | 0.9% |
| 29 | VSTMVERASTEM INC | 1.8M | $6.9M | 0.6% |
| 30 | ZNTLZENTALIS PHARMACEUTICALS INC | 1.4M | $6.9M | 0.6% |
| 31 | RLMDRELMADA THERAPEUTICS INC | 935,000 | $6.5M | 0.6% |
| 32 | OCULOCULAR THERAPEUTIX INC | 600,000 | $5.9M | 0.5% |
| 33 | TRVITREVI THERAPEUTICS INC | 310,000 | $5.8M | 0.5% |
| 34 | BBOTBRIDGEBIO ONCOLOGY THERAPEUT | 700,000 | $5.3M | 0.5% |
| 35 | LYELLYELL IMMUNOPHARMA INC | 344,025 | $4.8M | 0.4% |
| 36 | IRDOPUS GENETICS INC | 1.1M | $4.6M | 0.4% |
| 37 | FDMT4D MOLECULAR THERAPEUTICS IN | 334,437 | $4.4M | 0.4% |
| 38 | NTLAINTELLIA THERAPEUTICS INC | 250,000 | $4.2M | 0.4% |
| 39 | VYGRVOYAGER THERAPEUTICS INC | 1.2M | $4.1M | 0.4% |
| 40 | BDSXBIODESIX INC | 180,000 | $4.1M | 0.4% |
| 41 | RCKTROCKET PHARMACEUTICALS INC | 1.0M | $3.4M | 0.3% |
| 42 | JBIOJADE BIOSCIENCES INC | 145,000 | $3.2M | 0.3% |
| 43 | SNWVSANUWAVE HEALTH INC | 306,140 | $3.1M | 0.3% |
| 44 | FBIOFORTRESS BIOTECH INC | 890,000 | $2.7M | 0.2% |
| 45 | DERMJOURNEY MED CORP | 350,000 | $2.5M | 0.2% |
| 46 | PHATPHATHOM PHARMACEUTICALS INC | 185,589 | $2.0M | 0.2% |
| 47 | INBXINHIBRX BIOSCIENCES INC | 20,291 | $1.9M | 0.2% |
| 48 | ENTAENANTA PHARMACEUTICALS INC | 125,000 | $1.8M | 0.2% |
| 49 | COAGHEMAB THERAPEUTICS HLDGS INC | 47,652 | $1.8M | 0.2% |
| 50 | TRAXFIRST TRACKS BIOTHERAPEUTICS | 65,000 | $1.3M | 0.1% |
| 51 | CGONCG ONCOLOGY INC | 17,789 | $1.3M | 0.1% |
| 52 | BIOHAVEN LTD | 77,915 | $1.2M | 0.1% |
| 53 | AVIRATEA PHARMACEUTICALS INC | 235,000 | $1.1M | 0.1% |
| 54 | KTTAPASITHEA THERAPEUTICS CORP | 2.0M | $1.1M | 0.1% |
| 55 | ADC THERAPEUTICS SA | 700,000 | $749,000 | 0.1% |
| 56 | OKYO PHARMA LTD | 375,204 | $562,806 | 0.1% |
| 57 | PTNPALATIN TECHNOLOGIES INC | 20,500 | $221,195 | 0% |
| 58 | ADGMADAGIO MED HLDGS INC | 18,444 | $13,353 | 0% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.